Position in ROIV
as of Mar 31, 2026
· filed Apr 24, 2026
Position Value
$554,000
-$9,113,350 QoQ
Shares Held
20,000
-95.5% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Capricorn Fund Managers Ltd holds $53,362,145 across 7 Biotechnology names. ROIV ranks #7 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZYME |
Zymeworks Inc.
|
1,007,210 | $25,220,538 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
369,400 | $14,480,480 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
|
534,079 | $7,722,782 | |
| 4 | VERA |
Vera Therapeutics, Inc.
|
64,604 | $2,599,018 | |
| 5 | TARS |
Tarsus Pharmaceuticals, Inc.
|
26,000 | $1,823,900 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
339,727 | $961,427 | |
| 7 | ROIV |
Roivant Sciences Ltd.
This page
|
20,000 | $554,000 |
All Filings in ROIV
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $554,000 | 20,000 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $9,667,350 | 445,500 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $3,003,305 | 198,500 | Shares | Sole | 2025-10-17 | |
| No filing history on record for this holder in this stock. | ||||||